Introductory month
$99
Subsequent rate
$149/month
Commitment
Three-month offer billed in full
Support
Messaging, check-ins and adjustments advertised
Shipping
Free
Formulation
Compounded prescription injection

The offer has two prices and one upfront period

The AgelessRx injection offer is advertised with a $99 first month, followed by $149 per month, on a three-month plan billed in full. The first-month discount should not be presented as an ongoing monthly cost. One promotional month plus two subsequent months calculates to $397, but the final checkout must confirm that amount and any additional charges before it can be treated as an invoice.

AgelessRx also mentions monthly plans. This review's price label applies to the stated three-month offer; it does not silently assign that promotional rate to a separate monthly selection.

What the supplied service includes

The page describes a personalized clinician-guided plan with ongoing check-ins, unlimited messaging and protocol adjustments. Shipping is described as free and discreet, and a US-licensed compounding pharmacy dispenses the prescription. These elements belong in the cost comparison because a vial-only purchase would not describe the same package of services.

Ask whether laboratory work is included, how prescription adjustments affect future shipments and whether changing the quantity changes the bill. A promise of unlimited adjustments does not automatically mean that every replacement vial or added laboratory test is supplied at no charge.

The shipment and the treatment period may differ

A three-month billing arrangement does not, by itself, show whether all medication arrives at once or in several shipments. Request the dispatch schedule and the quantity supplied at each stage. This matters for storage, travel and the amount of medication that might remain if treatment changes.

The provider discusses pharmacy-dependent shipping practices, including whether cold packs are used. The correct response to a concern about a warm or damaged package is to contact the dispensing team for product-specific guidance. An ice pack's condition alone is not a substitute for the pharmacy's stability assessment.

Evidence should match the current injection

AgelessRx publishes testimonials, customer survey figures and a research bibliography. These have different evidentiary roles. Customer feedback can describe experience; it cannot establish a controlled treatment effect. Research about growth-hormone pathways needs to be checked for the exact intervention and population before being applied to this prescription.

The current compounded injection is not FDA-approved. Discuss the purpose of the treatment, relevant risks and how progress will be evaluated with the clinician. Neither the subscription price nor a favorable customer response percentage tells a reader whether sermorelin is appropriate for their symptoms.

What happens if you stop during the paid period

AgelessRx says the subscription can be paused or canceled. Ask what that means for money already paid for three months, medication already dispensed and a refill that is being processed. Stopping a future renewal is different from receiving a refund for part of the current period.

For a longer budget, one $99 month and eleven $149 months total $1,738 if the same rates continue. This is an illustration, excluding unresolved extras, not an annual commitment recommendation. Confirm the next renewal price and due date in writing so the introductory offer does not obscure the ongoing expense.

Useful distinctions

  • Introductory and subsequent rates disclosed
  • Ongoing clinical messaging described
  • Free shipping

Limitations to weigh

  • Three months billed in full
  • Refund of unused prepaid period not established
  • Published survey is not a clinical trial

Sources & further reading

Official pages and evidence consulted for this article. Checked October 11, 2026. Provider pages establish advertised terms; they do not independently establish effectiveness.

  1. AgelessRx: Sermorelin Injection Provider
  2. FDA: Understanding the Risks of Compounded Drugs Regulatory